Placental passage of antidepressant medications.

Objective: This study determined the placental transfer of antidepressants and their metabolites.

Method: A total of 38 pregnant women taking citalopram, fluoxetine, paroxetine, or sertraline participated. Maternal and umbilical cord blood samples were obtained to determine antidepressant and metabolite concentrations.

Weight gain in breastfed infants of mothers taking antidepressant medications.

Background: Little is known about the physical development of infants who are exposed to antidepressant medications through breast milk.

Method: Seventy-eight breastfeeding women taking antidepressant medications were included in the study. Maternal mood was prospectively evaluated at 6, 12, and 18 months postpartum.

Birth outcomes after prenatal exposure to antidepressant medication.

Objective: The purpose of this study was to examine prospectively the incidence of congenital anomalies and neonatal complications after prenatal exposure to antidepressant medication.

Study Design: Birth outcomes were obtained from a review of obstetric and neonatal records of 138 women who were treated with selective serotonin reuptake inhibitor antidepressant medications (SSRIs) during pregnancy.

Results: The incidence of congenital anomalies in this study was 1.